Spindiag’s continued road to success: Expansion of Series A with an additional 4 million euros for market entry
Summary
Together, we now have a strengthened investor board that can guide our efforts to develop, produce and sell products that are even better tailored for the market.“ Manfred Hoffmann, Partner at WBG: „We are thrilled by how well the Spindiag system was conceived for use across healthcare sectors. In addition, Spindiag presented its pioneering system at this year’s ECCMID in Amsterdam, the prestigious European Congress for Clinical Microbiology and Infectious Diseases, thereby expanding its network of potential strategic partners. Dr. Mark Keller, Chief Product Officer and co-founder of Spindiag, sums up: „The positive response from the audience at the event, especially clinicians, confirms our view that the market urgently needs a simple, safe and efficient point-of-care diagnostic system for multidrug-resistant bacteria. Last but not least, thanks to our new investors we already have access to new decentralized implementation areas for diagnostics and other highly relevant sectors in healthcare.“ The compact analysis system developed by Spindiag seamlessly integrates into existing workflows in both hospitals and laboratories. Based on a comprehensively patented centrifugal microfluidic platform, the company is developing a point-of-care diagnostic system as a safe, simple and efficient rapid test for a wide range of infectious diseases.